{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:57:18Z","timestamp":1762642638721,"version":"3.41.2"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2022,3,16]]},"abstract":"<jats:p>Genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to provide valuable insight into the ever-changing variant makeup of the COVID-19 pandemic. More than three million SARS-CoV-2 genome sequences have been deposited in Global Initiative on Sharing All Influenza Data (GISAID), but contributions from the United States, particularly through 2020, lagged the global effort.<\/jats:p>","DOI":"10.1128\/jcm.01288-21","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T20:39:25Z","timestamp":1641415165000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Collaboration between Clinical and Academic Laboratories for Sequencing SARS-CoV-2 Genomes"],"prefix":"10.1128","volume":"60","author":[{"given":"Jeremy","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Genetics, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn E.","family":"Hawken","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corbin D.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Genetics, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Hagan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-4056","authenticated-orcid":true,"given":"Frederic","family":"Bushman","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Everett","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-3535","authenticated-orcid":true,"given":"Melissa B.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-4810","authenticated-orcid":true,"given":"Kyle G.","family":"Rodino","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2294"},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control and Prevention. 2020. COVID data tracker. Centers for Disease Control and Prevention Atlanta GA. https:\/\/covid.cdc.gov\/covid-data-tracker."},{"key":"e_1_3_2_4_2","unstructured":"Centers for Disease Control and Prevention. 2021. COVID-19 vaccination program operational guidance. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/vaccines\/covid-19\/covid19-vaccination-guidance.html."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00573-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.02.003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf6950"},{"key":"e_1_3_2_8_2","unstructured":"United States Food and Drug Administration. 2021. FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization. United States Food and Drug Administration Silver Spring MD. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-antibody-products-under."},{"key":"e_1_3_2_9_2","unstructured":"United States Food and Drug Administration. 2021. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. United States Food and Drug Administration Silver Spring MD. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2105280"},{"key":"e_1_3_2_11_2","unstructured":"United States Food and Drug Administration. 2021. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2\u2014letter to clinical laboratory staff and health care providers. United States Food and Drug Administration Silver Spring MD. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00913-21"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01659-21"},{"key":"e_1_3_2_14_2","unstructured":"GISAID. 2021. GISAID\u2014submission tracker global on\/privacy. https:\/\/www.gisaid.org\/submission-tracker-global\/."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00908-0"},{"key":"e_1_3_2_16_2","unstructured":"Centers for Disease Control and Prevention. 2021. CDC\u2019s role in tracking variants. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/cdc-role-surveillance.html."},{"key":"e_1_3_2_17_2","unstructured":"Centers of Disease Control and Prevention. 2021. SPHERES. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/spheres.html."},{"key":"e_1_3_2_18_2","unstructured":"United States Department of Health and Human Services. 2021. Biden administration announces actions to expand COVID-19 testing. United States Department of Health and Human Services Washington DC. https:\/\/www.hhs.gov\/about\/news\/2021\/02\/17\/biden-administration-announces-actions-expand-covid-19-testing.html."},{"key":"e_1_3_2_19_2","unstructured":"White House. 2021. Fact sheet: Biden administration announces $1.7 billion investment to fight COVID-19 variants. https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2021\/04\/16\/fact-sheet-biden-administration-announces-1-7-billion-investment-to-fight-covid-19-variants\/."},{"key":"e_1_3_2_20_2","unstructured":"Center of Medicare and Medicaid Services. 2021. Does a facility that performs surveillance testing to identify SARS- CoV-2 genetic variants need a CLIA certificate? Center of Medicare and Medicaid Services Baltimore MD."},{"key":"e_1_3_2_21_2","unstructured":"Oxford Nanopore Technologies. 2021. MinION Mk1B IT requirements. Oxford Nanopore Technologies Oxford United Kingdom. https:\/\/community.nanoporetech.com\/requirements_documents\/minion-it-reqs.pdf."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab528"},{"key":"e_1_3_2_23_2","unstructured":"ARTIC Network. 2021. SARS-CoV-2. https:\/\/artic.network\/ncov-2019."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpaa014"},{"key":"e_1_3_2_25_2","unstructured":"Glenn SHB Durand NC Mitra N Godinez PS Mahajan R Blackburn A Colaric ZL Theisen JWM Weisz D Dudchenko O Gnirke A Rao SSP Kaur P Aiden EL Presser AA. 2020. A rapid low cost and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing. bioRxiv 10.1101\/2020.04.25.061499."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.201800"},{"key":"e_1_3_2_27_2","unstructured":"Loman N Rowe W Rambaut A. 2021. ARTIC Network. https:\/\/artic.network\/ncov-2019\/ncov2019-bioinformatics-sop.html."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03456-20"},{"key":"e_1_3_2_29_2","unstructured":"World Health Organization. 2021. WHO\u2019s code of conduct for open and timely sharing of pathogen genetic sequence data 2 during outbreaks of infectious disease. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_30_2","unstructured":"Association for Public Health Laboratories. 2021. Recommendations for SARS-CoV-2 sequence data quality & reporting. Association for Public Health Laboratories Silver Spring MD."},{"key":"e_1_3_2_31_2","unstructured":"Centers for Disease Control and Prevention. 2021. Guidance for reporting SARS-CoV-2 sequencing results. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/reporting-sequencing-guidance.html."},{"key":"e_1_3_2_32_2","unstructured":"The University of Texas at Austin COVID-19 Modeling Consortium. 2021. Variant detection calculator. https:\/\/covid-19.tacc.utexas.edu\/dashboards\/variants\/."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01288-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01288-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T14:03:38Z","timestamp":1647439418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01288-21"}},"subtitle":[],"editor":[{"given":"Romney M.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,16]]}},"alternative-id":["10.1128\/jcm.01288-21"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01288-21","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"type":"print","value":"0095-1137"},{"type":"electronic","value":"1098-660X"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"2022-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01288-21"}}